FACT accreditation for cell therapy programs: what it certifies and how to read it
The Foundation for the Accreditation of Cellular Therapy (FACT) is a non-profit co-founded by the International Society for Cell & Gene Therapy (ISCT) and the American Society for Transplantation and Cellular Therapy (ASTCT). It accredits clinical programs, collection facilities and processing laboratories that handle hematopoietic progenitor cells and immune effector cells such as CAR-T, as well as cord blood banks. Each accreditation names the services and the standards a program was inspected against, which tells a manufacturer or sponsor far more than a hospital-level quality label.
The standards behind each accreditation
| Label in FACT's directory | Current standards document | Who holds it |
|---|---|---|
| FACT-JACIE Hematopoietic Cellular Therapy | FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing and Administration, Ninth Edition | Blood and marrow transplant programs and the collection and processing facilities that serve them |
| FACT Immune Effector Cell Therapy; FACT Immune Effector Cell Therapy (Stand-alone) | FACT-JACIE International Standards for Immune Effector Cells, Third Edition | CAR-T and other immune effector cell programs and laboratories; "Stand-alone" marks organizations accredited under these standards on their own (seven on 10 November 2026) |
| FACT Standards for Immune Effector Cells in the Community Clinical Setting | First Edition, published November 2025 | Community-based programs administering immune effector cell therapies |
| FACT Common Standards | FACT Common Standards for Cellular Therapies, Third Edition | Cell manufacturing and processing facilities (six on 10 November 2026) |
| NetCord-FACT Cord Blood Banking | NetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration, Eighth Edition (Version 8.2) | Cord blood banks |
FACT accreditation is valid for three years. Programs start the renewal process around their second anniversary, renewal includes an on-site inspection, and collection sites that serve a clinical program are inspected together with that program.
Reading an accreditation entry
- Clinical services: Hematopoietic Progenitor Cell Transplantation, Immune Effector Cellular Therapy, or both. Many transplant programs show immune effector cell therapy as a clinical service while their standard reads FACT-JACIE Hematopoietic Cellular Therapy, so the clinical service is a better signal of CAR-T capability than the standard name alone.
- Transplant types: adult or pediatric, allogeneic or autologous. An adult-autologous-only program and a combined adult and pediatric allogeneic center are different partners for referral and trial placement.
- Apheresis and marrow collection: "Collection for Administration" and "Collection for Further Manufacturing". The second is the one that matters for products manufactured from a patient's own cells, such as autologous CAR-T made from a leukapheresis collection.
- Processing types: "Minimal Manipulation" and "More than Minimal Manipulation". The latter covers processing that alters the cells' relevant biological characteristics and points to laboratories with deeper manufacturing capability.
- Service providers and accredited collection sites: some organizations, including American Red Cross apheresis units, are accredited as collection or processing service providers, and FACT names the hospitals where their collection sites are. The American Red Cross program in Philadelphia, for example, has an accredited collection site at Nemours Children's Hospital in Wilmington, Delaware.
- Cord blood types: related, unrelated, or currently not accepting new cord blood units.
Where the accredited programs are
On 10 November 2026 FACT's public directory showed 353 accredited organizations: 303 in its cellular therapy category and 50 cord blood banks. 261 were in the USA, and the rest were spread over 28 other countries and territories, among them Argentina, Australia, Brazil, Canada, China, India, Jordan, Saudi Arabia, Singapore, Taiwan, Turkey and the United Arab Emirates. 222 organizations showed Hematopoietic Progenitor Cell Transplantation and 205 showed Immune Effector Cellular Therapy as a clinical service. FACT's recent announcements of national or regional firsts include King Hussein Cancer Center in Jordan (July 2026), Ramaiah Memorial Hospital in South India (April 2026) and Hospital Auxilio Mutuo with the American Red Cross Puerto Rico Region (April 2026).
CAR-T after the REMS: why accreditation still shapes networks
On 27 June 2025 the FDA eliminated the Risk Evaluation and Mitigation Strategies for six autologous CD19- and BCMA-directed CAR-T products: Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta. Hospitals and clinics dispensing them no longer need REMS certification or on-site, immediate access to tocilizumab, while boxed warnings and medication guides stay in the labeling. That removed a regulatory gate; it did not remove the need for manufacturers, payers and sponsors to judge a site's quality system, and FACT accreditation is an inspected, service-specific form of evidence for that judgement.
The community setting is where the map is moving. FACT published its first-edition Standards for Immune Effector Cells in the Community Clinical Setting in November 2025, adapted from the FACT-JACIE immune effector cell standards, and on 1 September 2026 announced Tennessee Oncology as the first community-based oncology program accredited under them. On 10 November 2026 two organizations in the directory carried that standard.
Accreditation is also not the whole treating population. Real-world analyses presented by Florida Cancer Specialists & Research Institute at the 2026 ASCO Annual Meeting found similar quality and safety measures at accredited and non-accredited CAR-T sites; the authors cautioned that accreditation status alone may not fully capture a center's ability to administer CAR-T safely, and that the finding needs confirmation in further studies. For network planning, accredited programs are the inspected core, and non-accredited treaters are a separate segment to qualify on their own evidence.
Practical checks
- Accreditation attaches to a named program and to the services and standards shown for it, not to every department of the hospital that houses it.
- Program names change with mergers and rebranding, and directory addresses can keep an older name: the AdventHealth Orlando transplant and cellular therapy program sits at a URL that still reads "florida-hospital".
- Because accreditation runs on a three-year cycle, confirm current status in FACT's directory before contracting a site or naming it in a protocol.
- An accredited collection site can be in a different city or state from the program that holds the accreditation, which matters for courier routing and chain-of-identity planning.